TOKYO and MADISON, Wis., March 30, 2015 —Â FUJIFILM Holdings Corporation (President: Shigehiro Nakajima) (“Fujifilm”) and Cellular Dynamics International, Inc. (CEO: Robert Palay)Â (“CDI”), a leading developer and manufacturer of fully functioning human cells in industrial quantities, announced that the two companies have entered into a agreement whereby Fujifilm will acquire CDI via an all-cash tender offer to be followed by a second step merger. [Read more…]
Need Results for Your Stem Cell Company or Cord Blood Bank? BioInformant Shares Testimonials
Competing in the Stem Cell Marketplace is a Difficult Task
For executives operating a stem cell company or cord blood bank, competing in the marketplace is a difficult task.  You must analyze market conditions, predict industry trends, and capitalize on market changes before the competition. Especially within the rapidly evolving stem cell marketplace, it can be difficult to make educated, informed decisions that produce revenue growth for your company, while limiting failed products that won’t have demand in the marketplace. [Read more…]
Save the Cord Foundation and BioInformant Join Forces in Global Effort to Increase Cord Blood Banking Awareness
PRESS RELEASE;Â April 1, 2015
WASHINGTON, DC, and TUCSON, AZ
Press release available at PR Web:  http://www.prweb.com/
For expectant parents, there are thousands of decisions to make in a short amount of time, including clothes, cribs, names, birthing methods, medical procedures, and more. It can be overwhelming, especially given the short-time frame involved. In addition to these decisions, there is an often overlooked decision: what to do with the extremely valuable stem and progenitor cells contained within the umbilical cord of the expected newborn? There are three options, which are to publicly donate, to privately store, or to discard the umbilical cord as medical waste. Two of those decisions require research and action on behalf of the parents, while the third is what happens when sufficient awareness and education has not been provided to allow parents to make an informed, educated decision. [Read more…]
WideCells – Stem Cell Biotechnology and Regenerative Medicine in the 21st Century
WideCells is a new and innovative stem cell technology and regenerative medicine company. It was founded by the CEO João Andrade and the CFO Lopes Gil. Dr Peter Hollands later joined as CSO bringing experience from other UK and international stem cell banks, clinical transplantation, teaching and research.
The first operations for WideCells were in Portugal, following on to the acquisition of the Spanish company Nacersalud to begin operations in Spain.
The continued success of operations in Portugal and Spain has led to the development of [Read more…]
Case Law & Legal Updates for the Cord Blood Banking Market
Major Cord Blood Industry Change in 2015
Although we are only a few months into 2015, the cord blood banking market has already been experiencing rapid change.
The industry has seen structural advances occur, including a recent announcement of the Board of Directors for the Cord Blood Association, an  international nonprofit that  promotes the storage and use of cord blood and related tissues, such as cord tissue and placenta.
There have been major research advances as well. In one major example, a porcine animal study was conducted by the Mayo Clinic to evaluate the safety and feasibility of cord blood-derived mononuclear cells (UBC-MNC) for use in promoting regeneration in pediatric congenital heart disease (CHD).
There have even been major clinical advances made already in 2015, with CryoSave leading and sponsoring a multicentre clinical trial following GCP-ICHÂ standards, to determine if Cerebral Palsy can be addressed by infusing stem cells derived from umbilical cord blood and cord tissue into patients.
However, no understanding of the cord blood market is complete without a consideration of recent case law and significant legal decisions, which brings us to the focus on this market update.
Cord Blood Case Law & Legal Updates
Currently, there are three legal situations of which cord blood market participants should be aware: [Read more…]